Biological
Natural Killer Cell clinical trials
Keep track of what changes. Save the Natural Killer Cell studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
56 studies that test it; most in 2016 (22)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 22 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 55
Fuda Cancer Hospital, Guangzhou (19) · M.D. Anderson Cancer Center (5) · National University Hospital, Singapore (4) · St. Jude Children's Research Hospital (2) · Southwest Hospital, China (2) · Dana-Farber Cancer Institute (1) · New Approaches to Neuroblastoma Therapy Consortium (1) · National Heart, Lung, and Blood Institute (NHLBI) (1)
Often tested with
Tested in the same studies.
Interleukin-2 (4) · Dinutuximab (3) · Cyclophosphamide (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Cetuximab (2) · Trastuzumab (2) · Lenalidomide (1) · Bortezomib (1)
Studies
Open first, then newest update. How each study uses Natural Killer Cell is read from its arms, and is right about nine times in ten.
Testing it · 56
- Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07411599Written as NK Cells
- NK Cell Injection for Advanced Solid TumorsNot yet recruitingPhase 1BOE Technology Group Co., Ltd.NCT07784777Written as NK CELLS
- A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent GlioblastomaRecruitingPhase 1M.D. Anderson Cancer CenterNCT07579208Written as NK Cells
- A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingPhase 1Peking University First HospitalNCT06641648Written as NK cell
- A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)RecruitingPhase 1M.D. Anderson Cancer CenterNCT05834244Written as NK Cells
- Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and GanglioneuroblastomaRecruitingPhase 3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT07375563Written as irinotecan, temozolomide, dinutuximab beta, NK-cell product
- Quadruple Immunotherapy for NeuroblastomaRecruitingPhase 2Hong Kong Children's HospitalNCT05754684Written as Natural killer cell
- Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer CellsRecruitingPhase 1Nationwide Children's HospitalNCT04254419Written as NK cells
- NK Cell Infusion for Remission Consolidation in AML: A Phase II TrialNot yet recruitingPhase 2Hospital de Clinicas de Porto AlegreNCT06783478Written as NK cell infusion
- Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid LeukemiaNot yet recruitingPhase 1/2German Cancer Research CenterNCT05319249Written as NK cells
- Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial CarcinomaActive, not recruitingEarly Phase 1Dana-Farber Cancer InstituteNCT06318871Written as Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
- Natural Killer Cells and Bortezomib to Treat CancerCompletedPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT00720785Written as NK cells
- Therapy for Children With Advanced Stage NeuroblastomaCompletedPhase 2St. Jude Children's Research HospitalNCT01857934Written as natural killer cell infusion
- Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell TransplantationCompletedPhase 1Institut Paoli-CalmettesNCT01853358Written as NK Cell infusion
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingPhase 1New Approaches to Neuroblastoma Therapy ConsortiumNCT02573896Written as NK Cells
- NK Cells Treatment for COVID-19CompletedPhase 1Xinxiang medical universityNCT04280224Written as NK Cells
- Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownPhase 2Nanfang Hospital, Southern Medical UniversityNCT05171309Written as NK cell
- Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AMLTerminatedPhase 2Technische Universität DresdenNCT02229266Written as NK cells
- Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory NeuroblastomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT00698009Written as Natural Killer Cell Infusion
- Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid TumorsCompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT02857920Written as NK immunotherapy
See all 56 studies that test Natural Killer Cell →
Given in every arm · 10 — Natural Killer Cell is usual care beside what is tested
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06434363Written as Tafasitamab and NK cells
- Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid TumorsNot yet recruitingPhase 1/2BOE Technology Group Co., Ltd.NCT07551778Written as NK Cells
- NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01875601Written as NK Cell Infusion
- A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020TerminatedPhase 1Vall d'Hebron Institute of OncologyNCT05385705Written as NK cells
- Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk NeuroblastomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02650648Written as NK cells
- Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and LymphomaCompletedPhase 2St. Jude Children's Research HospitalNCT01700946Written as natural killer cell infusion
- NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid DiseasesCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT01370213Written as NK Cells
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and LeukemiasCompletedPhase 1National Cancer Institute (NCI)NCT01287104Written as Natural Killer (NK) Cell Infusion
- A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or LymphomasCompletedPhase 1St. Jude Children's Research HospitalNCT02130869Written as CD133+ selected autologous stem cell infusion
- Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney CancerCompletedPhase 2National Cancer Institute (NCI)NCT00328861Written as Natural Killer (NK) Lymphocytes